Development of the patient experience questionnaire for parents of pediatric patients (PEQP)
Permalink
Citation
Kaipio , J , Karisalmi , N , Hiekkanen , K , Stenhammar , H & Lahdenne , P 2019 , Development of the patient experience questionnaire for parents of pediatric patients (PEQP) . in F Lau , J A Bartle-Clar , G Bliss , E M Borycki , K L Courtney , A M-H Kuo , A Kushniruk , H Monkman & A V Roudsari (eds) , Improving Usability, Safety and Patient Outcomes with Health Information Technology . Studies in Health Technology and Informatics , vol. 257 , IOS PRESS , Amsterdam , pp. 200-205 , Information Technology & Communications in Health , Victoria , British Columbia , Canada , 14/02/2019 . https://doi.org/10.3233/978-1-61499-951-5-200
| Title: | Development of the patient experience questionnaire for parents of pediatric patients (PEQP) |
| Author: | Kaipio, Johanna; Karisalmi, N.; Hiekkanen, K.; Stenhammar, H.; Lahdenne, P. |
| Other contributor: |
Lau, Francis
Bartle-Clar, John A. Bliss, Gerry Borycki , Elizabeth M. Courtney , Karen L. Kuo, Alex Mu-Hsing Kushniruk , Andre Monkman, Helen Roudsari, Abdul Vahabpour |
| Contributor organization: | HUS Children and Adolescents Children's Hospital |
| Publisher: | IOS PRESS |
| Date: | 2019 |
| Language: | eng |
| Number of pages: | 6 |
| Belongs to series: | Improving Usability, Safety and Patient Outcomes with Health Information Technology |
| Belongs to series: | Studies in Health Technology and Informatics |
| ISBN: | 978-1-61499-950-8 978-1-61499-951-5 |
| ISSN: | 0926-9630 |
| DOI: | https://doi.org/10.3233/978-1-61499-951-5-200 |
| URI: | http://hdl.handle.net/10138/327656 |
| Abstract: | Patient experience (PX) is an important evaluation criterion for quality in healthcare. Compared to patient satisfaction, however less research has focused on the development of instruments to measure experiences of patients and their families. In the article, we describe the process of developing a PX questionnaire for the parents of pediatric patients in the context of children's hospital and illustrate the questionnaire items for measuring PX. The phases of the development process included retrospective interviews, description of the themes influencing PX and the metrics for measuring PX, as well as iterative development of three versions of questionnaires including data gathering and factor analysis. The final versions of the surveys suggested for implementation at the hospitals include eight PX statements for the outpatient clinic and five statements for the ward. Compared to satisfaction surveys, the developed surveys emphasize the aspects of parent's attitude towards the illness, support for families, and daily arrangements with a child patient. © 2019 American Psychological Association Inc. All rights reserved. |
| Subject: |
children's hospital
measurement parent patient experience pediatric patient questionnaire Hospitals Measurement Pediatrics Quality control Development process Evaluation criteria Iterative development Patient experiences Patient satisfaction Pediatric patients Surveys article child clinical article controlled study factor analysis female human interview male outpatient department satisfaction adult child parent relation hospital patient satisfaction patient-reported outcome retrospective study Adult Child Factor Analysis, Statistical Hospitals, Pediatric Humans Parents Patient Reported Outcome Measures Patient Satisfaction Retrospective Studies Surveys and Questionnaires 3123 Gynaecology and paediatrics |
| Peer reviewed: | Yes |
| Rights: | cc_by_nc |
| Usage restriction: | openAccess |
| Self-archived version: | publishedVersion |
Files in this item
Total number of downloads: Loading...
| Files | Size | Format | View |
|---|---|---|---|
| SHTI257_0200.pdf | 292.8Kb |
View/ |
This item appears in the following Collection(s)
-
Articles from TUHAT CRIS [50573]
Related items
Showing items related by title, author, creator and subject.
-
(2019)Background Supportive-care use of granulocyte colony-stimulating factor (G-CSF) in pediatric acute myeloid leukemia (AML) remains controversial due to a theoretical increased risk of relapse and limited impact on neutropenic complications. We describe the use of G-CSF in patients treated according to NOPHO-AML 2004 and DB AML-01 and investigated associations with relapse. Procedure Patients diagnosed with de novo AML completing the first week of therapy and not treated with hematopoietic stem cell transplantation in the first complete remission were included (n = 367). Information on G-CSF treatment after each course (yes/no) was registered prospectively in the study database and detailed information was gathered retrospectively from each center. Descriptive statistics were used to describe G-CSF use and Cox regression to assess the association between G-CSF and risk of relapse. Results G-CSF as supportive care was given to 128 (35%) patients after 268 (39%) courses, with a large variation between centers (0-93%). The use decreased with time-the country-adjusted odds ratio was 0.8/diagnostic year (95% confidence interval [CI] 0.7-0.9). The median daily dose was 5 mu g/kg (range 3-12 mu g/kg) and the median cumulative dose was 75 mu g/kg (range 7-1460 mu g/kg). Filgrastim was used in 82% of G-CSF administrations and infection was the indication in 44% of G-CSF administrations. G-CSF was associated with increased risk of relapse-the adjusted hazard ratio was 1.5 (95% CI 1.1-2.2). Conclusions G-CSF as supportive care was used in a third of patients, and use decreased with time. Our results indicate that the use of G-CSF may be associated with an increased risk of relapse.
-
(2018)Summary Objective Navigated transcranial magnetic stimulation (nTMS) is becoming increasingly popular in noninvasive preoperative language mapping, as its results correlate well enough with those obtained by direct cortical stimulation (DCS) during awake surgery in adult patients with tumor. Reports in the context of epilepsy surgery or extraoperative DCS in adults are, however, sparse, and validation of nTMS with DCS in children is lacking. Furthermore, little is known about the risk of inducing epileptic seizures with nTMS in pediatric epilepsy patients. We provide the largest validation study to date in an epilepsy surgery population. Methods We compared language mapping with nTMS and extraoperative DCS in 20 epilepsy surgery patients (age range 9‐32 years; 14 children and adolescents). Results In comparison with DCS, sensitivity of nTMS was 68 specificity 76 positive predictive value 27 and negative predictive value 95 Age, location of ictal‐onset zone near or within DCS‐mapped language areas or severity of cognitive deficits had no significant effect on these values. None of our patients had seizures during nTMS. Significance Our study suggests that nTMS language mapping is clinically useful and safe in epilepsy surgery patients, including school‐aged children and patients with extensive cognitive dysfunction. Similar to in tumor surgery, mapping results in the frontal region are most reliable. False negative findings may be slightly more likely in epilepsy than in tumor surgery patients. Mapping results should always be verified by other methods in individual patients.
-
(2020)Background This study evaluated the safety and efficacy of teduglutide in pediatric patients with short bowel syndrome-associated intestinal failure (SBS-IF). Methods A 24-week, phase III trial with 2 randomized, double-blind teduglutide dose groups and a nonblinded standard of care (SOC) arm was used; patients received 0.025 mg/kg or 0.05 mg/kg teduglutide once daily. Safety end points included treatment-emergent adverse events (TEAEs) and growth parameters. The primary efficacy/pharmacodynamic end point was the number of patients who achieved a >= 20% reduction in parenteral support (PS) from baseline at week 24. Results All 59 enrolled patients completed the study (0.025 mg/kg, n = 24; 0.05 mg/kg, n = 26; SOC, n = 9). Baseline demographics and disease characteristics were comparable among groups. TEAEs were reported by 98% and 100% of patients in the teduglutide and SOC groups, respectively. The most common TEAEs in the teduglutide-treated groups were pyrexia and vomiting. The primary end point was achieved by 13 (54.2%), 18 (69.2%), and 1 (11.1%) patients who received 0.025 mg/kg teduglutide, 0.05 mg/kg teduglutide, and SOC, respectively (P <0.05 vs SOC). Both 0.025-mg/kg and 0.05-mg/kg teduglutide groups showed clinically significant reductions in PS volume (P <0.05 vs SOC), PS calories, days per week and hours per day of PS infusions, and increases in enteral nutrition and plasma citrulline at week 24 compared with baseline. Two (8.3%, 0.025 mg/kg teduglutide) and 3 patients (11.5%, 0.05 mg/kg teduglutide) achieved enteral autonomy. Conclusion The safety profile of teduglutide was similar to that reported previously in children and adults. Treatment with teduglutide was associated with significant reductions in PS for pediatric patients with SBS-IF over 24 weeks.